Pero Bokarica

Dr. Pero Bokarica

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

Verified
Journal Article
Open access
PDF file
AHAdelina Hrkac
Adelina Hrkac
Luka BulićLuka Bulić
Luka Bulić
Petar BrlekPetar Brlek
Petar Brlek
SNSven Nikles
Sven Nikles
PBPero Bokarica
Pero Bokarica
Dragan PrimoracDragan Primorac
Dragan Primorac
Exosomes, nanoscale extracellular vesicles released by virtually all cell types, have emerged as pivotal mediators of intercellular communication and play a crucial role in the pathophysiology of numerous acute and chronic diseases, including a wide spectrum of urological disorders. By acting as sophisticated biological shuttles, exosomes transport a rich and highly specific molecular cargo—comprising proteins, lipids, messenger RNAs, microRNAs, and other nucleic acids—that reflects the physiological or pathological state of their cell of origin. Owing to these unique properties, exosomes are increasingly recognized as promising biomarkers for the diagnosis, prognosis, and monitoring of a broad range of inflammatory, degenerative, and neoplastic diseases. Beyond their diagnostic value, exosomes have attracted considerable attention as therapeutic tools, given their ability to promote tissue regeneration, modulate immune responses, and serve as potential targeted drug-delivery systems for small molecules, biologics, vaccines, and gene-based therapies. Notably, exosomes recapitulate many of the beneficial biological effects traditionally attributed to stem cells, while potentially offering a more practical alternative. As cell-free entities, they may reduce—though not entirely eliminate—several risks associated with cell transplantation, such as uncontrolled proliferation and immune rejection, and they raise fewer ethical concerns, making them attractive candidates for regenerative and precision medicine. In urology, the diagnostic, prognostic, and therapeutic applications of exosomes are rapidly expanding, with particularly promising advances observed in bladder, prostate, and kidney diseases. Growing evidence also supports their relevance in a variety of benign urological conditions, including erectile dysfunction, male infertility, neurogenic bladder, urethral stricture disease, stress urinary incontinence, and bladder pain syndrome. This review synthesizes contemporary knowledge on the biological significance and clinical potential of exosomes in urology, highlighting their emerging role as biomarkers and therapeutics, with a special focus on benign urological disorders. We emphasize that the current evidence base in benign urology is largely preclinical, and that clinical translation, although promising, remains at an early stage.

15 May 2023 in Urologia Internationalis
Verified
Journal Article
Open access
PDF file
PBPero Bokarica
Pero Bokarica
MAMaša Alfirević
Maša Alfirević
AHAdelina Hrkać
Adelina Hrkać
AGAna Magdalena Glas
Ana Magdalena Glas
ITIgor Tomašković
Igor Tomašković
Dear Editor,We have read an article recently published by Korkes and associates with great interest [1]. This interesting systematic review makes us question different aspects of radical and reconstructive surgery of muscle-invasive bladder cancer. The emphasis of the article is on the mortality rate after cystectomy. As expected, it resulted in mortality rates that are significantly lower in countries with major developed economies than in developing countries. Mortality rates are also lower in high-volume centers than those in low-volume centers.Interestingly, Canada simultaneously had the lowest rate of in-hospital mortality and the highest rate of 90-day mortality (90M). Korkes et al. did not offer a possible explanation for these results. The answer could be the importance of the availability of a center experienced in managing complications. Another topic from this article that deserves attention is the proportion of patients treated with cystectomy among patients who have an absolute indication for this type of surgery. If we know that radical surgical treatment is “the gold standard” for patients with pT2–pT4 M0 disease, the percentage of 18.9% of the patients treated with radical surgery is extremely low [2]. An alternative to operative treatment is trimodal treatment, which according to the guidelines is reserved for small, solitary tumors or patients with contraindications for surgery [3]. We are well aware that both of these groups of patients make up a minor part of the total number of candidates for radical treatment. The third question from this article is the choice of urinary diversion. It was shown that only 10.4% of patients receive continent diversion, which is similar to the results of Hautmann and associates from 2015, where the percentage in institutions worldwide is 15%, it reaches 30–45% in leading oncology centers, and only in pioneering institutions amounts to about 75% [4].Given that our Department of Urology performs about 100 cystectomies per year, of which 40–50% are with orthotopic derivation, the above questions are extremely interesting to us. We believe there is a unique answer to all three open questions. The centralization of patients in high-volume centers brings with it (1) a lower mortality rate, as stated in this article; (2) an adequate form of treatment considering the significantly higher percentage of patients treated with radical cystectomy; (3) the most appropriate form of urinary diversion.All the authors declare no conflict of interests.This work has not received any funding.Pero Bokarica, Masa Alfirevic, Adelina Hrkac, Ana Magdalena Glas, and Igor Tomaskovic participated in the writing of the manuscript. Pero Bokarica, Masa Alfirevic, and Adelina Hrkac did the concept and design of the manuscript.